Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20365215 | 0.85 | EPHX2 (0.76) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL17645926 | 0.85 | EPHX2 (0.74) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL17645838 | 0.85 | EPHX2 (0.59) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL26697130 | 0.83 | AKR1B1 (0.62) | EPHX2NR1H4HDAC6AKR1B1HTT | |
| SCHEMBL17646045 | 0.82 | EPHX2 (0.71) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL26697181 | 0.80 | KLKB1 (0.53) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL28158250 | 0.79 | EPHX2 (0.67) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL26107231 | 0.77 | HDAC3 (0.80) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL4489127 | 0.77 | P2RX7 (0.54) | AKR1B1 | |
| SCHEMBL20359069 | 0.77 | MAPT (0.64) | NR1H4HDAC3HDAC8HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212999-A | Pyrrolopyrimidine compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-12-27 | — | — | CN | disclosed |
| CN-117164591-A | Pyrrolopyrimidine compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023226580-A1 | PYRROLOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 中国医学科学院药物研究所 | 2023-11-30 | — | — | WO | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (US) | 2015-10-08 | — | — | US | disclosed |
| WO-2014064131-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014064131-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | EPHX2 1940/4885NR1H4 3566/4885HDAC3 1259/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | EPHX2 2154/4885NR1H4 3942/4885HDAC3 1658/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | EPHX2 1940/4885NR1H4 3566/4885HDAC3 1259/4885 |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | EPHX2 3695/4885NR1H4 4383/4885HDAC3 3523/4885 |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | EPHX2 2158/4885NR1H4 4622/4885HDAC3 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.